Latest research progress in IIb/IIIa receptor inhibitor treatment of acute coronary syndrome

Acute coronary syndrome (ACS) is a serious acute cardiovascular event threatening human health, including unstable angina, non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction, and sudden death caused by the above-mentioned cardiac problems. Direct percutaneous coronary intervention (PCI) has been proved an effective method of treatment for ACS. During PCI therapy, the use of glycoprotein IIb/IIIa receptor antagonists can reduce thrombosis complications in ACS patients.